Antiangiogenic Therapies in Non-Small-Cell Lung Cancer
نویسندگان
چکیده
منابع مشابه
Non-small-cell lung cancer: targeted therapies
Chemotherapy: is it still enough? The major progresses in understanding cancer biology and the mechanism of oncogenesis have allowed the development of several potential molecular target drugs for cancer treatment, which are components of signaling pathways or metabolic processes contributing to the acquisition of cancer phenotype. A general better tolerability, owing to a milder toxicity profi...
متن کاملContrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype
The vascular endothelial growth factor (VEGF) pathway is a clinically validated antiangiogenic target for non-small cell lung cancer (NSCLC). However, some contradictory results have been reported on the biological effects of antiangiogenic drugs. In order to evaluate the efficacy of these drugs in NSCLC histological subtypes, we analyzed the anticancer effect of two anti-VEGFR2 therapies (suni...
متن کاملNovel therapies in non-small cell lung cancer.
Over the last years, several new systemic cancer therapy strategies have been introduced to turn the growing insights of molecular aberrations involved in the development and progression of lung cancer into better treatment options fort the patients. This review presents some of the most important biological targets and biomarkers relevant in the treatment of non-small cell lung cancer. Especia...
متن کاملMaintenance therapies in advanced non-small-cell lung cancer
Non-small-cell lung cancer (NSCLC) has the second highest incidence of any newly diagnosed cancer and also has the highest mortality of any cancer type [1]. The majority of patients present with late-stage disease, by which time systemic therapy (chemotherapy) has become the primary treatment and platinum doublet chemotherapy is the first-line choice among patients with advanced disease (stage ...
متن کاملMulti-Targeted Therapies in Non-Small Cell Lung Cancer
E-mail: [email protected] Tel (Fax): 86-22-2352 2919 ABSTRACT Current treatment modalities provide limited improvement in the natural course of lung cancer, and prognosis remains poor. Lung cancer is a malignancy with great molecular heterogeneity. The complexity of the signaling process leading to cancer cell proliferation and to the neoplastic phenotype supports the necessity of interferi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Oncology
سال: 2018
ISSN: 1718-7729
DOI: 10.3747/co.25.3747